miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

about

Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.Targeting the IDO1 pathway in cancer: from bench to bedside

P2860

Q55454951-77825DBB-58ED-4F25-A766-1D0EB5699055 Q58803138-46ABFAA3-F1FE-4F06-8BF8-1D2002FC3411

P2860

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

Item

http://www.wikidata.org/entity/Q52569152

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

@en

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

@nl

type

Item

label

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

@en

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

@nl

prefLabel

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

@en

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

@nl

P1476

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

@en

P2093

Jiajia Xia

http://www.w3.org/2001/XMLSchema#string

Ken H Young

http://www.w3.org/2001/XMLSchema#string

Lei Wang

http://www.w3.org/2001/XMLSchema#string

Ling Li

http://www.w3.org/2001/XMLSchema#string

Mingzhi Zhang

http://www.w3.org/2001/XMLSchema#string

Munish Kumar

http://www.w3.org/2001/XMLSchema#string

Qian Huang

http://www.w3.org/2001/XMLSchema#string

Qing Yi

http://www.w3.org/2001/XMLSchema#string

Qipan Deng

http://www.w3.org/2001/XMLSchema#string

Xiaodong Ma

http://www.w3.org/2001/XMLSchema#string

P2860

MicroRNA targeting specificity in mammals: determinants beyond seed pairing

The impact of microRNAs on protein output

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Mechanisms of type-I- and type-II-interferon-mediated signalling

Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.

Masked Chimeric Antigen Receptor for Tumor-Specific Activation.

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

miR-301a as an NF-κB activator in pancreatic cancer cells.

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

P2888

s13045-018-0600-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13045-018-0600-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yong Li

P577

2018-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103597399

http://www.w3.org/2001/XMLSchema#string

P698

29685162

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5914051

http://www.w3.org/2001/XMLSchema#string

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

about

P2860

P2860

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932